ClinicalTrials.gg
CompletedNCT00919711Updated Jul 28, 2020Results posted

Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy

A Phase 3 interventional study of Actonel® and Denosumab in Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
870
Allocation
Randomized
Ages
55 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
5th of 64
870 · median 90
Started
2009
with 4 others
Phase 3
24 of 64
2 open now
Registered
14th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 5th largest by enrollment, is one of 5 that started in 2009, is one of 24 in phase 3, and was the 14th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

A randomized, open label study to assess the safety and effectiveness of Denosumab, administered every 6 months and Actonel ® (Risedronate), administered monthly in post menopausal women transitioned from weekly or daily Alendronate therapy.

03

Conditions studied

  • Osteoporosis

Keywords

  • Menopausal Osteoporosis
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory, post menopausal women aged 55 years or older at screening. Have received their first prescription of daily or weekly alendronate therapy, for the treatment for post menopausal osteoporosis at least 1 month prior to screening. Use of raloxifene, calcitonin or hormone replacement therapy (HRT) prior to alendronate treatment will be allowed. Prior and/or current use of vitamin D and calcium will be allowed.
  • Has stopped oral alendronate therapy (is denoted as non-persistent) before the screening visit or, is still taking oral alendronate therapy but does not take on a regular basis (this will be assessed by the completion of a compliance questionnaire at screening).
  • Provide signed before any study-specific procedures are conducted.

Exclusion criteria

Exclusion Criteria:

  • Any prior or current use of medications prescribed for osteoporosis treatment other than oral daily alendronate, calcium and vitamin D. Prior use of raloxifen, calcitonin or HRT before alendronate therapy was started will be allowed.
  • to Actonel® or any ingredient of Actonel® tablets.
  • or poorly tolerant of alendronate therapy.
  • Active gastric or duodenal ulcer.
  • Known sensitivity to mammalian cell derived products.
  • Known intolerance to calcium supplements.
  • within the last 5 years (except for cervical or basal cell carcinoma).
  • Vitamin D deficiency (serum 25-OH vitamin D less than 20ng/mL (equivalent to 49.9 nanomoles per Liter) at screening.
  • Current hypo- or hypercalcemia based on the central laboratory reference ranges.
  • Uncontrolled hyper- or hypothyroidism (stable on antithyroid therapy or post-ablation is allowed, if the laboratory results from screening show that thyroid stimulating hormone (TSH) is within the normal range).
  • Any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta, Paget's disease of bone that may interfere with the interpretation of the findings.
  • Height, weight or girth which may preclude accurate dual x-ray absorptiometry (DXA measurements).
  • Fewer than 2 lumbar vertebrae (L1-L4) able to be evaluated by DXA.
  • Known to have tested positive for .
  • Previous participation in clinical trials with denosumab within the last 12 months (regardless of treatment).
  • Any laboratory abnormality, physical or psychiatric disorder (including substance abuse in last 12 months) which, in the opinion of the investigator, will prevent the subject from giving written or completing the study or interfere with the interpretation of the study results.
  • Currently enrolled in or within 30 days of ending another device or drug trial(s).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
870 participants (actual)

Study arms

  • Experimental
    Denosumab 60 mg

    Drug: Denosumab

  • Active comparator
    Risedronate 150 mg QM

    Drug: Actonel®

Interventions

  • Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).

    Also known as: Risedronate

  • Denosumab 60 mg, once every 6 months, Subcutaneous

06

What researchers measure

Primary outcomes

  1. Total Hip BMD Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry

    Time frame: Baseline to month 12

Secondary outcomes

  1. Serum CTX Percent Change From Baseline at Month 1

    Serum Type-1 Collagen C-Telopeptide Percent Change From Baseline at Month 1

    Time frame: Baseline to month 1

  2. Femoral Neck BMD Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry

    Time frame: Baseline to month 12

  3. Lumbar Spine BMD Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry

    Time frame: Baseline to month 12

07

Results

Posted Dec 12, 2012

Participant flow

Participants were enrolled from 19 October 2009 through 4 January 2011

Participant flow — Overall Study
MilestoneRisedronate 150 mg QMDenosumab 60 mg Q6M
Started435435
Completed402422
Not completed3313
Withdrew: Withdrawal by subject157
Withdrew: Adverse event133
Withdrew: Other12
Withdrew: Administrative decision01
Withdrew: Lost to follow-up20
Withdrew: Death10
Withdrew: Noncompliance10

Outcome measures

PrimaryTotal Hip BMD Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry

Time frame:
Baseline to month 12
Reported as:
Mean · Percent Change From Baseline
Total Hip BMD Percent Change From Baseline at Month 12
Percent Change From BaselineRisedronate 150 mg QMDenosumab 60 mg Q6M
Total Hip BMD Percent Change From Baseline at Month 120.5 (0.2 to 0.7)2.0 (1.8 to 2.3)
Statistical analysis
  • Risedronate 150 mg QM vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 · Mean difference (net): 1.6 · 95% CI 1.2 to 2.0Denosumab - Risedronate
SecondarySerum CTX Percent Change From Baseline at Month 1

Serum Type-1 Collagen C-Telopeptide Percent Change From Baseline at Month 1

Time frame:
Baseline to month 1
Reported as:
Median · Percent Change From Baseline
Serum CTX Percent Change From Baseline at Month 1
Percent Change From BaselineRisedronate 150 mg QMDenosumab 60 mg Q6M
Serum CTX Percent Change From Baseline at Month 1-17.0 (-36.8 to -1.6)-77.7 (-85.9 to -67.6)
Statistical analysis
  • Risedronate 150 mg QM vs Denosumab 60 mg Q6M · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryFemoral Neck BMD Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry

Time frame:
Baseline to month 12
Reported as:
Mean · Percent Change From Baseline
Femoral Neck BMD Percent Change From Baseline at Month 12
Percent Change From BaselineRisedronate 150 mg QMDenosumab 60 mg Q6M
Femoral Neck BMD Percent Change From Baseline at Month 120.0 (-0.4 to 0.3)1.4 (1.0 to 1.7)
Statistical analysis
  • Risedronate 150 mg QM vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 · Mean difference (net): 1.4 · 95% CI 0.9 to 1.8Denosumab - Risedronate
SecondaryLumbar Spine BMD Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry

Time frame:
Baseline to month 12
Reported as:
Mean · Percent Change From Baseline
Lumbar Spine BMD Percent Change From Baseline at Month 12
Percent Change From BaselineRisedronate 150 mg QMDenosumab 60 mg Q6M
Lumbar Spine BMD Percent Change From Baseline at Month 121.1 (0.7 to 1.5)3.4 (3.1 to 3.8)
Statistical analysis
  • Risedronate 150 mg QM vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 · Mean difference (net): 2.3 · 95% CI 1.8 to 2.8Denosumab - Risedronate

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risedronate 150 mg QM—35/429 (8.2%)0/429 (0%)
Denosumab 60 mg Q6M—33/429 (7.7%)0/429 (0%)
Most frequent serious events
Showing 10 of 75
Most frequent serious events
EventRisedronate 150 mg QMDenosumab 60 mg Q6M
Atrial fibrillationCardiac disorders0/4292/429
Coronary artery stenosisCardiac disorders2/4290/429
Radius fractureInjury, poisoning and procedural complications0/4292/429
ArthralgiaMusculoskeletal and connective tissue disorders0/4292/429
OsteoarthritisMusculoskeletal and connective tissue disorders1/4292/429
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4291/429
Cerebral ischaemiaNervous system disorders0/4292/429
Cerebrovascular accidentNervous system disorders0/4292/429
Atrial flutterCardiac disorders1/4290/429
Cardiac arrestCardiac disorders1/4290/429

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Risedronate 150 mg QMDenosumab 60 mg Q6MTotal
Mean67.7 ± 6.867.8 ± 7.067.7 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Risedronate 150 mg QMDenosumab 60 mg Q6MTotal
Female435435870
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Risedronate 150 mg QMDenosumab 60 mg Q6MTotal
White or Caucasian425424849
Hispanic or Latino6713
Asian437
Japanese011
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014 Jan;58:48-54. doi: 10.1016/j.bone.2013.10.006. Epub 2013 Oct 17. PubMed 24141036 ↗
  • Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwinski E, Bone HG, Wang C, Huang S, Chines A, Lems W, Brown JP. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2020 Jan;31(1):181-191. doi: 10.1007/s00198-019-05233-x. Epub 2019 Nov 28. PubMed 31776637 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2009 to primary completion in Dec 2011, 27 months.

Results were first posted in Dec 2012, 11 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 27 months is above that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2009
First posted
Jun 12, 2009
StartActual
Sep 1, 2009
Primary completionActual
Dec 21, 2011
CompletionActual
Mar 5, 2012
Results first posted
Dec 12, 2012
Last update
Jul 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00919711
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 12, 2009
Start date
Sep 1, 2009
Primary completion
Dec 21, 2011
Completion
Mar 5, 2012
Results posted
Dec 12, 2012
Last update
Jul 28, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion